1. Scrip
  2. >>Business
  3. >>Strategy

Pressed Sanofi CEO Hopes For Positive Dupixent Launch, Praluent Ruling

 
• By Sten Stovall

Sanofi's CEO Olivier Brandicourt's reassuring 2017 guidance relies on continued cost savings, a successful launch of its Dupixent biologic, and winning a US legal case that threatens its PCSK9 inhibitor Praluent.

Sanofi reported slightly better than expected fourth-quarter results and reassuring guidance for 2017 on Feb. 8 - but analysts said real growth remains elusive for the French drugmaker and that its immediate prospects largely hinge on launching its Dupixent (duplimumab) therapy for atopic dermatitis and also winning a pending patent infringement case that threatens sales of its PCSK9 inhibitor Praluent (alirocumab).

The Paris-based group – which Olivier Brandicourt has revamped since taking over as CEO in April 2015 – also faces...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.

Asia Deal Watch: Otsuka’s Taiho Licenses LSD1 Inhibitor Rights To Benz

 
• By Joseph Haas, Lisa Takagi, Jung Won Shin, Vibha Ravi, and Sushmita Panda

Plus deals involving BioAge/JiKang, Sanyou/Medicovestor, AriBio/Acino, Intragrand/Transpire, Kaken/Twocells, Sumitomo/Novo Nordisk, NIBEC/Undisclosed, Formosa/Adalvo, Drug Farm/Amoytop, Lupin/SteinCares and Lupin/Honeywell.

More from Business